Articles related to CONTRACEPTION/BIRTH CONTROL

Although research exists on the impact of CNS stimulants used in pregnancy, only a few small studies have looked at atomoxetine and pregnancy outcomes. This large cohort study of 4.2 million pregnancies ending in live births in northern Europe and the US reviewed nearly 1,000 pregnancies exposed to atomoxetine in the first trimester. Compared with non-exposed pregnancies, there was no observed increase in major congenital abnormalities with atomoxetine use in the first trimester.

Today, it is possible to safely treat CML throughout pregnancy with little danger to the unborn child, as TKIs can now be safely administered during the later stages of pregnancy, according to new research. After beginning or continuing TKI therapy, a sizable majority of patients can be managed by observation alone, and disease control can be attained. IFN-α may be given in any trimester with little harm to the fetus if active treatment is necessary. Most essential, however, is a multidisciplinary strategy to offer clear and concise guidance to enable both the mother and the family to participate in the decision-making process.

During pregnancy and the postpartum period, the body is subjected to abnormal stress, raising the possibility of eye and vision-related conditions and complications. Refractive changes, central serous chorioretinopathy, Purtscher-like retinopathy, diabetes, hypertension, and immunologic diseases are examples of eye and vision-related conditions and complications. Although diabetic retinopathy that develops during pregnancy usually resolves on its own after delivery, women are still at risk of progression for up to a year after delivery.

Pregnant women who filled prescriptions for bupropion, citalopram, escitalopram, fluoxetine, or sertraline during pregnancy (antidepressant-exposed cohort) and pregnant women who did not fill an antidepressant prescription within 90 days of the start of their pregnancy through delivery (control group) were the subjects of the study conducted by researchers from Brigham and Women’s Hospital in the United States. The main finding concerned the frequency of ADHD, autism spectrum disorder (ASD), behavioral disorder, developmental coordination disorder, developmental speech or language disorder, intellectual disability, any NDDs, and specific learning disorders among the children of the women in the study.

Some studies in children have reported a relationship between antidepressant use in pregnancy and neurodevelopment disorders after birth. In this analysis of 145,702 antidepressant-exposed and 3,032,745 unexposed pregnancies, crude results suggested up to a doubling in risk of neurodevelopmental outcomes. Significantly, however, no association was observed after balancing for confounding variables.

Nearly 20,000 mother-child pairs were tracked over a median follow-up of 4 years. After adjusting for maternal risk factors and their children’s own ultra-processed food intake, physical activity, and sedentary time, maternal consumption of ultra-processed foods during the child-rearing period was associated with overweight or obesity in offspring with a 26% higher risk in the group with the highest maternal ultra-processed food consumption.